XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$28.19 USD
-1.66 (-5.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $28.49 +0.30 (1.06%) 6:44 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
XOMA Royalty Corporation [XOMA]
Reports for Purchase
Showing records 161 - 180 ( 332 total )
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
April and 2015 Emerging Pharmaceuticals CatalystsThis report contains brief updates on the following: BIOD, BMRN, ICPT, LXRX, OMER, RCPT, RLYP, SGMO, VTAE, XOMA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Servier''s Additional Investment in Diabetic Nephropathy Expands the Market Potential for Gevokizumab; Reiterate OUTPERFORM and $17 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q4 2014 Financials: Cash Runway Lasts Through Anticipated Catalysts in 2015; Reiterate OUTPERFORM and $17 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
XOMA 358 Demonstrates Initial Clinical Proof-of-Concept: It''s No Longer Just About Gevokizumab; Reiterate OUTPERFORM and Increasing PT to $17.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events from the Week of March 9th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
January and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences- Upcoming Events for the Week of Dec 22
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
December and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
3Q Recap; Behcet''s Results Likely in January, with Pre-Validated Data
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials: Cash Runway Through 2015 Covers Gevokizumab Clinical Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Trial of Gevokizumab Underway in Ultra Orphan PG
Provider: Roth Capital Partners, Inc.